Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

Source: 
Motley Fool
snippet: 

Bristol Myers Squibb (NYSE:BMY) capped the week with a new approval from the Food and Drug Administration (FDA). On Friday, the regulator gave the green light for two of the pharmaceutical giant's drugs, Opdivo and Yervoy, to be used in combination to treat a form of mesothelioma. This is a form of cancer that affects the mesothelium, the thin layer of tissue covering many of the body's internal organs.